KRKhaled Rahal

Khaled Rahal

*This is an algorithmically generated author record based on publicly available information.

Khaled Rahal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EPV019/#309 Ovarian metastases from breast cancer: a series of nine cases

    by K Ben Hamida, I Zemni, N Boujelbene, A Mlouka, I Zidi, S Essghaier, R Chargui, K Rahal

    Objectives Development of ovarian metastasis (OM) during the course of primary breast cancer (PBC) is uncommon and associated with poor prognosis. The objective of this study is to review the characteristic clinical and imaging features of OM from PBC. Methods A retrospective study of nine patients treated in our institution, who had documented OM from breast carcinoma between 2005 and 2020. Results At the time of PBC diagnosis, the mean age was 44 (range 31–64). In five cases, the PBC was unilateral. Histological subtypes were invasive ductal carcinoma in five patients and invasive lobular carcinoma in four patients. ER and PR were positive in eight cases. HER2 was positive in two cases. Five patients had locally advanced breast carcinoma. Four patients had synchronous ovarian metastases. Only three patients underwent breast surgery. Main symptoms of OM were pelvic pain and abdominal distension. An elevated CA 125 level was found in seven cases while CA 15–3 level was increased in eight cases. In four cases, pulmonary and bone metastases were simultaneously diagnosed with OM occurrence. All patients underwent ovarian surgery. Seven patients had bilateral OM. Ascites and peritoneal carcinomatosis were seen respectively in six and three patients. Time to occurrence of OM after PBC was a median of 25 months. The median follow-up period after OM assessment was 18 months. Conclusions The evaluation of ovarian lesion years after breast cancer is challenging and rise the possibility of a metastatic lesion. Imaging, serum tumor markers and histology may provide valuable tools in the assessment of ambiguous cases.

  • Pure Ductal Carcinoma in Situ in The Male Breast: A Rare Entity

    by Saida Sakhri, Olfa Jaidane, Malek Bouhani, Olfa Adouni, Salma Kammoun, Riadh Chargui, Khaled Rahal

    Male breast cancer,ductal carcinoma in situ,treatment


  • Open Access

    Perineal psödo-kontinan kolostomi üzerinde alt rektal karsinom rekürrensinin başarılı tedavisi: Bir olgu sunumu ve literatürün gözden geçirilmesi

    by Malek Bouhani̇, Olfa Jai̇dane, Mohamed Amine Boui̇da, Radhi Bennaceur, Riadh Chargui̇, Khaled Rahal

    Recurrence of lower rectal carcinoma on perineal pseudo-continent colostomy is rarely reported in the literature. It presents a real challenge for the physician. The aim of this case report was to document an exceptional recurrence and how to manage it. A 56-year-old man presented with stage II adenocarcinoma of the lower rectum. He received concomitant chemoradiation followed by abdominoperineal resection with perineal pseudo-continent colostomy. Three years later, he developed a local recurrence of his prior adenocarcinoma, on the perineal pseudo-continent colostomy. He underwent wide excision, followed by reconstruction with a rectus abdominis myocutaneous flap with an inferior pedicle and an oblique skin paddle. He underwent adjuvant chemotherapy. The patient is free of disease with three years follow up. Extended resection should be considered as an initial treatment for locally recurrent rectal cancer.

  • Open Access

    Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients

    by Ines Zemni, Montassar Ghalleb, Ichraf Jbir, Maher Slimane, Jamel Ben Hassouna, Tarek Ben Dhieb, Hatem Bouzaiene, Khaled Rahal

    Histologically, node-negative breast cancer generally have a good prognosis. However, 10 to 30% of the cases present local relapses or metastasis. This group of people has high chances of remission if detected early. The aim of this study is to identify financial affordability for developing countries to adjust treatment. We selected 405 patients with histologically confirmed node-negative breast cancer in our institution between January 2001 and December 2003. Patients with metastasis were excluded. The statistical analysis was conducted using SPSS ver. 18 (SPSS, Inc., Chicago, Illinois). The medial age was 51 years old. The medial tumor size was 35.4 mm. Clinically, 67.2% of the patients were staged cT2 and 63.2%, cN1i. Breast conservation was achieved in 41% of cases. In the histologic examination, the medial size was 30 mm. Grade III tumors were found in 50.1% of patients and positive hormonal receptors in 53.4%. The mean number of lymph nodes was 14. Eight patients had neoadjuvant chemotherapy. Adjuvant locoregional radiation and adjuvant chemotherapy were prescribed respectively in 70.6 and 64.4% of cases. 59.7% had adjuvant hormonal therapy. The follow-up showed 17.7% cases of relapse either locally or in a metastatic way in a mean time of 57.4 months. The disease-free survival at 5 years was 82.1%, and the overall survival for the same period was 91.5%. The histologic tumor size and the grade and number of lymph node dissected were shown to be influencing the disease-free survival. Radiation therapy and hormone therapy showed improved disease-free survival and overall survival. Our study found interesting results that may help personalize the treatment especially for patient living in underdeveloped countries, but further studies are needed to evaluate those and more accessible prognostic factors for a more accessible healthcare.


  • Cancer du sein secondaire après traitement pour maladie de Hodgkin. À propos de sept cas

    by J. Ben Hassouna, M. Slimène, H. Boussen, H. Bouzaiene, F. Khomsi, R. Chargui, L. Kochbati, M.H. Mtaallah, A. Gamoudi, F. Benna, et al.


  • Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie.

    by L Kochbati, H Boussen, F Benna, Z Belhaj Ali, A Gammoudi, N Bouaouina, M Besbes, L Ghilen, K Rahal, M Maalej